AAM welcomes House approval of bill to boost generic competition

The Association for Accessible Medicines (AAM) has welcomed House passage of Q1/Q2 legislation embedded in the Give Kids a Chance Act, while observers note the measure sits within a wider policy debate about how to accelerate affordable competition in the USA medicines market.

AAM president and chief executive John Murphy III said the bill would help shorten approval timelines by allowing the American medicines regulator to identify which inactive ingredients make a proposed generic formulation fail the Q1/Q2 sameness test. He urged the Senate to move quickly, though analysts caution the legislation forms only one part of a broader reform agenda.

The bipartisan measure, reintroduced this Congress after earlier committee work, seeks to reduce administrative delays that can slow the arrival of competing products after patent expiry. The AAM argues that timelier disclosure from the regulator will help manufacturers adjust formulations more efficiently.